Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD
Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …
available therapies only modestly improve clinical outcomes. Observational studies report …
Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: the COMBINE trial
Background Higher serum phosphate and fibroblast growth factor-23 (FGF23) levels may be
modifiable to prevent cardiovascular disease in CKD. Short-term studies have reported …
modifiable to prevent cardiovascular disease in CKD. Short-term studies have reported …
Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD
T Isakova, A Barchi-Chung, G Enfield… - Clinical Journal of the …, 2013 - journals.lww.com
Background Elevated levels of fibroblast growth factor 23 (FGF23) are associated with
increased risk of adverse outcomes in patients with CKD. Reducing dietary phosphate …
increased risk of adverse outcomes in patients with CKD. Reducing dietary phosphate …
Phosphate and cardiovascular disease beyond chronic kidney disease and vascular calcification
S Disthabanchong - International journal of nephrology, 2018 - Wiley Online Library
Phosphate is essential for life but its accumulation can be detrimental. In end‐stage renal
disease, widespread vascular calcification occurs as a result of chronic phosphate load. The …
disease, widespread vascular calcification occurs as a result of chronic phosphate load. The …
Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease
JJ Scialla, M Wolf - Nature Reviews Nephrology, 2014 - nature.com
Disturbances in phosphate homeostasis are common in patients with chronic kidney
disease. As kidney function declines, circulating concentrations of phosphate and the …
disease. As kidney function declines, circulating concentrations of phosphate and the …
Phosphate: a stealthier killer than previously thought?
The kidneys excrete excess dietary phosphate, and patients with chronic kidney disease
may suffer from phosphate overload and hyperphosphatemia. In chronic kidney disease …
may suffer from phosphate overload and hyperphosphatemia. In chronic kidney disease …
[HTML][HTML] A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease
The diagnosis of chronic kidney disease (CKD) confers dismal clinical outcomes regardless
of whether patients are initiating dialysis and face a median survival of only 2–3 years or …
of whether patients are initiating dialysis and face a median survival of only 2–3 years or …
Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk
ND Toussaint, E Pedagogos, SJ TAN, SV Badve… - …, 2012 - Wiley Online Library
There is an intimate association between mineral and bone disorders in chronic kidney
disease (CKD) and the extensive burden of cardiovascular disease (CVD) in this population …
disease (CKD) and the extensive burden of cardiovascular disease (CVD) in this population …
Fibroblast growth factor 23 and the future of phosphorus management
M Wolf - Current opinion in nephrology and hypertension, 2009 - journals.lww.com
FGF23 is emerging as a novel and exciting biomarker that may help identify which CKD
patients might benefit most from aggressive management of disordered phosphorus …
patients might benefit most from aggressive management of disordered phosphorus …
FGF23 in chronic kidney disease
P Wahl, M Wolf - Endocrine FGFs and Klothos, 2012 - Springer
Chronic kidney disease (CKD) is a growing public health epidemic that is associated with a
markedly increased risk of cardiovascular mortality. Disordered mineral metabolism and …
markedly increased risk of cardiovascular mortality. Disordered mineral metabolism and …